Dually acting nonclassical 1,4-dihydropyridines promote the anti-tuberculosis (Tb) activities of clofazimine

Fabian Lentz, Norbert Reiling, G. Spengler, Annamária Kincses, Andrea Csonka, J. Molnár, Andreas Hilgeroth

Research output: Contribution to journalArticle

Abstract

The number of effective antituberculotic drugs is strongly limited to four first-line drugs in standard therapy. In case of resistances second-line antibiotics are used with a poor efficacy and tolerability. Therefore, novel antituberculotic drugs are urgently needed. We synthesized novel nonclassical 1,4-dihydropyridines and evaluated their antituberculotic properties depending on substituent effects. Preferred substituents could be identified. As related classical 1,4-dihydropyridines are known as inhibitors of the transmembrane efflux pump ABCB1 in cancer cells, we wondered whether a use of our compounds may be of favour to enhance the antituberculotic drug efficacy of the second-line antituberculotic drug clofazimine, which is a known substrate of ABCB1 by a suggested inhibition of a corresponding efflux pump in Mycobacterium tuberculosis (Mtb). For this, we determined the ABCB1 inhibiting properties of our compounds in a mouse T-lymphoma cell line model and then evaluated the drug-enhancing properties of selected compounds in a co-application with clofazimine in our Mtb strain. We identified novel enhancers of clofazimine toxicity which could prevent clofazimine resistance development mediated by an efflux pump activity.

Original languageEnglish
Article number2873
JournalMolecules
Volume24
Issue number16
DOIs
Publication statusPublished - Aug 8 2019

Fingerprint

Clofazimine
tuberculosis
Tuberculosis
drugs
efflux
Pharmaceutical Preparations
Pumps
pumps
Mycobacterium tuberculosis
Cells
antibiotics
cultured cells
toxicity
inhibitors
mice
Toxicity
1,4-dihydropyridine
therapy
Lymphoma
cancer

Keywords

  • Antibacterial activity
  • Inhibition
  • Structure-activity
  • Substituent
  • Synthesis

ASJC Scopus subject areas

  • Analytical Chemistry
  • Chemistry (miscellaneous)
  • Molecular Medicine
  • Pharmaceutical Science
  • Drug Discovery
  • Physical and Theoretical Chemistry
  • Organic Chemistry

Cite this

Dually acting nonclassical 1,4-dihydropyridines promote the anti-tuberculosis (Tb) activities of clofazimine. / Lentz, Fabian; Reiling, Norbert; Spengler, G.; Kincses, Annamária; Csonka, Andrea; Molnár, J.; Hilgeroth, Andreas.

In: Molecules, Vol. 24, No. 16, 2873, 08.08.2019.

Research output: Contribution to journalArticle

Lentz, Fabian ; Reiling, Norbert ; Spengler, G. ; Kincses, Annamária ; Csonka, Andrea ; Molnár, J. ; Hilgeroth, Andreas. / Dually acting nonclassical 1,4-dihydropyridines promote the anti-tuberculosis (Tb) activities of clofazimine. In: Molecules. 2019 ; Vol. 24, No. 16.
@article{830f00d288414303b5e9ab67c03d5805,
title = "Dually acting nonclassical 1,4-dihydropyridines promote the anti-tuberculosis (Tb) activities of clofazimine",
abstract = "The number of effective antituberculotic drugs is strongly limited to four first-line drugs in standard therapy. In case of resistances second-line antibiotics are used with a poor efficacy and tolerability. Therefore, novel antituberculotic drugs are urgently needed. We synthesized novel nonclassical 1,4-dihydropyridines and evaluated their antituberculotic properties depending on substituent effects. Preferred substituents could be identified. As related classical 1,4-dihydropyridines are known as inhibitors of the transmembrane efflux pump ABCB1 in cancer cells, we wondered whether a use of our compounds may be of favour to enhance the antituberculotic drug efficacy of the second-line antituberculotic drug clofazimine, which is a known substrate of ABCB1 by a suggested inhibition of a corresponding efflux pump in Mycobacterium tuberculosis (Mtb). For this, we determined the ABCB1 inhibiting properties of our compounds in a mouse T-lymphoma cell line model and then evaluated the drug-enhancing properties of selected compounds in a co-application with clofazimine in our Mtb strain. We identified novel enhancers of clofazimine toxicity which could prevent clofazimine resistance development mediated by an efflux pump activity.",
keywords = "Antibacterial activity, Inhibition, Structure-activity, Substituent, Synthesis",
author = "Fabian Lentz and Norbert Reiling and G. Spengler and Annam{\'a}ria Kincses and Andrea Csonka and J. Moln{\'a}r and Andreas Hilgeroth",
year = "2019",
month = "8",
day = "8",
doi = "10.3390/molecules24162873",
language = "English",
volume = "24",
journal = "Molecules",
issn = "1420-3049",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
number = "16",

}

TY - JOUR

T1 - Dually acting nonclassical 1,4-dihydropyridines promote the anti-tuberculosis (Tb) activities of clofazimine

AU - Lentz, Fabian

AU - Reiling, Norbert

AU - Spengler, G.

AU - Kincses, Annamária

AU - Csonka, Andrea

AU - Molnár, J.

AU - Hilgeroth, Andreas

PY - 2019/8/8

Y1 - 2019/8/8

N2 - The number of effective antituberculotic drugs is strongly limited to four first-line drugs in standard therapy. In case of resistances second-line antibiotics are used with a poor efficacy and tolerability. Therefore, novel antituberculotic drugs are urgently needed. We synthesized novel nonclassical 1,4-dihydropyridines and evaluated their antituberculotic properties depending on substituent effects. Preferred substituents could be identified. As related classical 1,4-dihydropyridines are known as inhibitors of the transmembrane efflux pump ABCB1 in cancer cells, we wondered whether a use of our compounds may be of favour to enhance the antituberculotic drug efficacy of the second-line antituberculotic drug clofazimine, which is a known substrate of ABCB1 by a suggested inhibition of a corresponding efflux pump in Mycobacterium tuberculosis (Mtb). For this, we determined the ABCB1 inhibiting properties of our compounds in a mouse T-lymphoma cell line model and then evaluated the drug-enhancing properties of selected compounds in a co-application with clofazimine in our Mtb strain. We identified novel enhancers of clofazimine toxicity which could prevent clofazimine resistance development mediated by an efflux pump activity.

AB - The number of effective antituberculotic drugs is strongly limited to four first-line drugs in standard therapy. In case of resistances second-line antibiotics are used with a poor efficacy and tolerability. Therefore, novel antituberculotic drugs are urgently needed. We synthesized novel nonclassical 1,4-dihydropyridines and evaluated their antituberculotic properties depending on substituent effects. Preferred substituents could be identified. As related classical 1,4-dihydropyridines are known as inhibitors of the transmembrane efflux pump ABCB1 in cancer cells, we wondered whether a use of our compounds may be of favour to enhance the antituberculotic drug efficacy of the second-line antituberculotic drug clofazimine, which is a known substrate of ABCB1 by a suggested inhibition of a corresponding efflux pump in Mycobacterium tuberculosis (Mtb). For this, we determined the ABCB1 inhibiting properties of our compounds in a mouse T-lymphoma cell line model and then evaluated the drug-enhancing properties of selected compounds in a co-application with clofazimine in our Mtb strain. We identified novel enhancers of clofazimine toxicity which could prevent clofazimine resistance development mediated by an efflux pump activity.

KW - Antibacterial activity

KW - Inhibition

KW - Structure-activity

KW - Substituent

KW - Synthesis

UR - http://www.scopus.com/inward/record.url?scp=85070685185&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85070685185&partnerID=8YFLogxK

U2 - 10.3390/molecules24162873

DO - 10.3390/molecules24162873

M3 - Article

VL - 24

JO - Molecules

JF - Molecules

SN - 1420-3049

IS - 16

M1 - 2873

ER -